Virtual Library

Start Your Search

Tali Voloshin



Author of

  • +

    EP1.06 - Mesothelioma (ID 196)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Mesothelioma
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.06-07 - In Vivo Studies of Tumor Treating Fields to Upper Torso in Combination with Chemotherapy Show No Additional Toxicities (ID 1789)

      08:00 - 18:00  |  Author(s): Tali Voloshin

      • Abstract
      • Slides

      Background

      Tumor Treating Fields (TTFields) are low intensity, intermediate frequency alternating electric fields targeting rapidly dividing cells. TTFields (200 kHz) are FDA-approved for the treatment of glioblastoma based on phase 3 studies demonstrating efficacy and a high safety profile. TTFields are currently being tested as a treatment option for other solid tumors in the brain, abdomen, and torso. We evaluated if the safety profile of TTFields is maintained at various frequencies in the upper torso.

      Method

      TTFields (150 kHz) were applied for 1-4 weeks using the Novo-TTF 100 system to rat and rabbit torso at 2-3 V/cm, which are intensities and frequencies known to be effective for the treatment of NSCLC and mesothelioma. The safety of TTFields in combination with liposomal doxorubicin and cyclophosphamide or paclitaxel was tested in animals. Throughout the treatment course, all animals underwent daily clinical examination by a certified experienced veterinarian and their body weight was determined on a weekly basis. Extensive blood workup, ECG, and temperature measurements were performed in the rabbit experiments. At the end of treatment, animals were euthanized and an experienced independent pathologist performed histological comparative evaluation of all major internal organs.

      Result

      No changes in the following parameters were observed in activity level, food intake, drinking, stools, motor neurological status, and respiration. Further, no changes in weight were observed between the TTFields treated and relevant control groups. No significant changes were observed in complete blood count and differential between TTFields treated animals and relevant control groups. Histological analysis did not reveal any increase in pathological findings in the TTFields treated animal groups.

      Conclusion

      These results demonstrate the safety of TTFields application at frequencies of 150 kHz to the torso. No additional toxicities were observed with the combination of TTFields and chemotherapy agents vs chemotherapy agents alone. This work further supports the safety profile of TTFields and offers opportunities for combining TTFields with various chemotherapy agents in lung cancers.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.06 - Mesothelioma (ID 169)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Mesothelioma
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.06-17 - Tumor Treating Fields (150 kHz) Combined with Cisplatin or Pemetrexed Inhibits Mesothelioma Cells in Vitro and in Vivo (ID 1904)

      09:45 - 18:00  |  Author(s): Tali Voloshin

      • Abstract
      • Slides

      Background

      Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer mostly linked to asbestos exposure. The standard of care (SOC) therapy for unresectable MPM is cisplatin plus pemetrexed. Tumor Treating Fields (TTFields) therapy is an effective anti-neoplastic treatment modality delivered via noninvasive application of low intensity, intermediate frequency, alternating electric fields. We explored the potential use of TTFields alone and in combination with SOC as a treatment for MPM.

      Method

      NCI-H2052 and MSTO-211H cells were treated at various TTFields frequencies for 72 hours using the inovitro system. The combined treatment of TTFields and cisplatin or pemetrexed was tested by applying TTFields at the optimal frequency together with various drug concentrations. Cell counts, clonogenic potential and induction of apoptosis were determined. TTFields (1.2 V/cm, 150 kHz) were applied for 8 days to rats injected to the intrapleural cavity with IL-45 cells, and overall survival was tested. TTFields (2-3 V/cm) were applied to the torsos of Sprague-Dawley rats at 150 kHz for 2 weeks and all major internal organs were histologically compared.

      Result

      TTFields optimal frequency was 150 kHz for both human cell lines. TTFields application (1.1 V/cm, 72 hours) at 150 kHz led to 45%-51% reduction in cell counts and 46%-64% additional reduction in clonogenic potential. The combined treatment of TTFields and cisplatin or pemetrexed led to a significant reduction in cell count, induction of apoptosis, and reduced clonogenic potential as compared to each modality alone (p<0.0001(. TTFields significantly prolonged the survival of rats compared to control group. Histological analysis did not reveal any increase in pathological findings with 150 kHz TTFields applied to the rat torso.

      Conclusion

      These results demonstrate that TTFields are a potentially effective and safe treatment for mesothelioma. The combination of TTFields with cisplatin or pemetrexed further enhances treatment efficacy. These preclinical data are consistent with those reported in a recent MPM phase 2 study (STELLAR; EF-23 trial, NCT02397928), which showed improved overall survival for combined treatment with TTFields plus pemetrexed and a platinum agent compared with historical control data, with no increase in systemic toxicity. The combination of TTFields with pemetrexed or cisplatin may further enhance treatment efficacy in mesothelioma.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.